RxDoctor Payments Data

Thuan le, MD

Infectious Disease · Murrieta, CANPI 1396842704

Payments from drug & device makers

$150,570in general payments, 2019–2025

Across 912 payments — averaging $165.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Melinta Therapeutics, LLC$40K
  • AbbVie$20K
  • Cumberland Pharmaceuticals, Inc.$18K
  • Merck$17K
  • Ferring Pharmaceuticals Inc.$12K
  • GRT US Holding, Inc.$9K
  • plus $33K from 26 others

What the payments were for

  • Consulting fees$13,99910%
  • Speaking & faculty fees$89,87863%
  • Travel & lodging$9,4107%
  • Food & beverage$27,61119%
  • Education$1,6981%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$150,570 in reported general payments places this provider in the 90th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$175,206
Medicare patients
415
Services billed
19,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate48$480,870
ArikayceAmikacin Liposomal/Neb.Accessr24$353,731
JulucaDolutegravir/Rilpivirine39$241,869
CabenuvaCabotegravir/Rilpivirine28$178,918
BiktarvyBictegrav/Emtricit/Tenofov Ala43$171,116
Egrifta SvTesamorelin Acetate15$108,042
GenvoyaElviteg/Cob/Emtri/Tenof Alafen24$94,600
TriumeqAbacavir/Dolutegravir/Lamivudi13$45,795
Daptomycin20$32,903
Meropenem13$5,717
ErtapenemErtapenem Sodium15$5,611
Cefepime Hcl25$4,114
Vancomycin Hcl29$3,402
Rifampin44$2,337
Cephalexin18$2,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$1,314$480,87048 claims
Viiv Healthcare CompanyJuluca, Cabenuva, Triumeq$4,192$466,58280 claims
Insmed, Inc.Arikayce$4,875$353,73124 claims
GileadBiktarvy, Genvoya$273$265,71667 claims
Theratechnologies Inc.Egrifta Sv$859$108,04215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 856 infectious disease providers in California.

Other infectious disease in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →